2021
Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose
Krantz MS, Kwah JH, Stone CA, Phillips EJ, Ortega G, Banerji A, Blumenthal KG. Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose. JAMA Internal Medicine 2021, 181: 1530-1533. PMID: 34309623, PMCID: PMC8314170, DOI: 10.1001/jamainternmed.2021.3779.Peer-Reviewed Original Research
2019
Prevalence and characterization of chronic rhinosinusitis in patients with non‒cystic fibrosis bronchiectasis at a tertiary care center in the United States
Somani SN, Kwah JH, Yeh C, Conley DB, Grammer LC, Kern RC, Prickett M, Schleimer RP, Smith SS, Stevens WW, Tan BK, Welch KC, Peters AT. Prevalence and characterization of chronic rhinosinusitis in patients with non‒cystic fibrosis bronchiectasis at a tertiary care center in the United States. International Forum Of Allergy & Rhinology 2019, 9: 1424-1429. PMID: 31589811, PMCID: PMC6913921, DOI: 10.1002/alr.22436.Peer-Reviewed Original ResearchConceptsPresence of CRSTertiary care centerChronic rhinosinusitisCare centerNon-cystic fibrosis bronchiectasisPrevalence of CRSConcomitant chronic rhinosinusitisRetrospective cohort studyGastroesophageal reflux diseasePeripheral eosinophil countPulmonary function testingTertiary medical centerNumerous comorbid conditionsTreatment of patientsUnited States populationBronchiectasis patientsFibrosis bronchiectasisReflux diseaseAllergic rhinitisCohort studyRadiographic evidenceAntibody deficiencyComorbid conditionsEosinophil countFunction testing